Treatment of Stage III Non-small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

AATS Postgraduate Course April 26, 2015 N2 - Current Evidence: Is There Role for Surgery? Is There a Role for Postop Radiation for Surprise N2? Linda W.

Advertisements

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Treatment of Stage I and II Non-small Cell Lung Cancer

Colloquium on Therapy of Right Heart Failure

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Volume 143, Issue 5, Pages e93S-e120S (May 2013)

The Role of Induction (Neoadjuvant) Chemotherapy in Stage IIIA NSCLC

Epidemiology and Treatment of Lung Cancer in Seattle

Hyperbaric Oxygenation in Cardiac and Pulmonary Disease

Volume 127, Issue 6, Pages (June 2005)

Air Pollution and Chest Disease

Special Treatment Issues in Non-small Cell Lung Cancer

Screening for Lung Cancer

Treatment of Malignant Pleural Effusion

The Lung Cancer Stage Page

Treatment of Small Cell Lung Cancer

Diagnostic Surgical Pathology in Lung Cancer

Volume 143, Issue 5, Pages e437S-e454S (May 2013)

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Volume 143, Issue 5, Pages e93S-e120S (May 2013)

Treatment of Stage I and II Non-small Cell Lung Cancer

Joshua E. Rosen, BASc, Hari B

The Stage Classification of Lung Cancer

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Treatment of Tobacco Use in Lung Cancer

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Treatment of Stage IV Non-small Cell Lung Cancer

Details and Difficulties Regarding the New Lung Cancer Staging System

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Decortication after 35 Years

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Joshua E. Rosen, BASc, Michelle C

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer Walter Weder, MD, Stéphane Collaud, MD,

Volume 143, Issue 5, Pages e121S-e141S (May 2013)

Treatment of Stage I and II Non-small Cell Lung Cancer

What’s new in stage III lung cancer?

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

George Blumenschein, MD, John V. Heymach, MD, PhD

Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response Ellis Ziel,

Volume 143, Issue 5, Pages e263S-e277S (May 2013)

Volume 155, Issue 1, Pages (January 2019)

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study Koji Kawaguchi, MD, Kohei Yokoi, MD, Hiroshi Niwa,

Methodology for Development of Guidelines for Lung Cancer

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

International Thymic Malignancies Interest Group: A Way Forward

Thoracic Surgery Survey on Lung Cancer Management

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer? Daniel J. Boffa, MD,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Mott Frank E. , MD, Sharma Neeraj , MD, Ashley Pandora CHEST

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Treatment of Stage III Non-small Cell Lung Cancer Nithya Ramnath, MD, Thomas J. Dilling, MD, Loren J. Harris, MD, FCCP, Anthony W. Kim, MD, FCCP, Gaetane C. Michaud, MD, FCCP, Alex A. Balekian, MD, MSHS, Rebecca Diekemper, MPH, Frank C. Detterbeck, MD, FCCP, Douglas A. Arenberg, MD, FCCP CHEST Volume 143, Issue 5, Pages e314S-e340S (May 2013) DOI: 10.1378/chest.12-2360 Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 1 [Section 2.1] Addition of cisplatin-based chemotherapy to radiotherapy improves survival in stage III NSCLC. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 2 [Section 2.2, 3.3] A depiction of the heterogeneous patient characteristics of stage III lung cancer and the inclusion of various patient subtypes into clinical studies evaluating treatment options for patients with stage III disease. PS = performance status; RT = radiotherapy. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 3 [Section 2.2] Concurrent vs sequential chemoradiotherapy treatment details. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 4 [Section 3.1] Randomized phase 3 trials of preoperative therapy followed by surgery vs surgery alone for stage III NSCLC. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 5 [Section 3.2] Outcomes of preoperatively identified N2 involvement with primary surgery. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 6 [Section 3.3] Randomized phase 3 trials of preoperative therapy followed by surgery vs chemoradiotherapy for stage III NSCLC. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 7 [Section 3.3] Survival of patients with stage IIIA (N2) lung cancer treated with CT/RT or CT/RT/S from the North American Intergroup Study 0139.65 A, Progression-free survival. B, Overall survival. The initial steeper slope of the trimodality arm demonstrates the importance of the perioperative mortality rate on the overall results of trimodality therapy. CT/RT = chemotherapy and radiotherapy; CT/RT/S = chemotherapy and radiotherapy followed by surgery. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 8 [Section 3.3.1] Selection criteria for trimodality therapy with surgery in patients with stage III (N2) lung cancer. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 9 [Section 3.3.2] Outcomes of patients with persistent N2 after induction therapy (ypN2) who underwent resection. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 10 [Section 3.3.2] Survival of patients having surgery after poor response to induction therapy. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 11 [Section 4.1] MLND: survival and recurrence data. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions

Figure 12 [Section 4.2] NSCLC adjuvant studies that included patients with stage III disease: survival with adjuvant chemotherapy. CHEST 2013 143, e314S-e340SDOI: (10.1378/chest.12-2360) Copyright © 2013 The American College of Chest Physicians Terms and Conditions